Midecamycin

Midecamycin
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

File:Midecamycin.png

Midecamycin.png

Midecamycin is a macrolide antibiotic used in the treatment of various bacterial infections. It is derived from the bacterium Streptomyces mycarofaciens. Midecamycin is particularly effective against Gram-positive bacteria and some Gram-negative bacteria.

Mechanism of Action[edit]

Midecamycin works by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, thereby preventing the translocation of peptides during translation. This action effectively halts bacterial growth and replication.

Pharmacokinetics[edit]

Midecamycin is administered orally and is well-absorbed from the gastrointestinal tract. It is metabolized in the liver and excreted primarily in the bile and, to a lesser extent, in the urine.

Clinical Uses[edit]

Midecamycin is used to treat a variety of infections, including:

Side Effects[edit]

Common side effects of midecamycin include:

Gastrointestinal disturbances such as nausea, vomiting, and diarrhea
Allergic reactions like rash and pruritus
Hepatotoxicity in rare cases

Contraindications[edit]

Midecamycin should not be used in patients with:

Known hypersensitivity to macrolide antibiotics
Severe liver disease

Drug Interactions[edit]

Midecamycin can interact with other medications, including:

Warfarin - increased risk of bleeding
Theophylline - increased serum levels of theophylline
Carbamazepine - increased serum levels of carbamazepine

History[edit]

Midecamycin was first isolated and identified in the 1970s. It has since been used in various countries for the treatment of bacterial infections, particularly in cases where patients are allergic to penicillin.

References[edit]

External Links[edit]

This medical article is a stub. You can help WikiMD by expanding the page.